Why the study?
Does plasma D-dimer level associate with cancer metastasis and progression in patients with various cancers?
Does plasma D-dimer level associate with cancer metastasis and progression in patients with various cancers?
Elevated plasma D-dimer levels are associated with the presence, clinical stage, and metastasis of various cancers, suggesting its potential as a prognostic biomarker.
Answers are grounded in this paper and cite their sources.
Elevated D-dimer may indicate cancer progression risk; hypothesis-generating and requires prospective validation before clinical adoption.
D-dimer is a widely used biomarker for indicating the activation of coagulation and fibrinolysis, and is reported to serve important roles in cancer progression. The aim of the current retrospective study was to investigate the association of D-dimer plasma level with the development of various cancers. Patients with breast (n=86), gastric (n=317), pancreatic (n=37), colon (n=153) and rectal (n=137) cancers and 92 healthy volunteers were assessed in the present study. Plasma levels of D-dimer in the patients and healthy controls were measured by immunoturbidimetric assays. The association of D-dimer levels with the clinicopathological features of patients were also determined. The plasma levels of D-dimer were significantly higher in patients with breast cancer (P=0.0022), gastric cancer (P<0.0001), pancreatic cancer (P=0.0003), colon cancer (P=0.0001) and rectal cancer (P=0.0028), compared with the healthy controls. It was also determined that the plasma D-dimer levels were positively associated with clinical cancer stage (P<0.05) and metastasis (P<0.05). These findings suggested that the plasma D-dimer level may be used as marker for predicting cancer metastasis and progression.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: